Regeneron Pharmaceuticals, Inc.;Institute for Research in Biomedicine (IRB);Yale University
发明人:
Andrew J. Murphy,Sean Stevens,Richard Flavell,Markus Gabriel Manz,Liang Shan
申请号：
US16672042
公开号：
US20200060244A1
申请日:
2019.11.01
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function； in modeling human pathogen infection of erythrocytes； in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state； in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors； in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors； in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy.
